Acinetobacter baumannii subunit vaccines: recent progress and challenges

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• Acinetobacter baumannii is a dangerous Gram-negative pathogen causing severe hospital infections.
• Multidrug resistance in A. baumannii necessitates novel therapeutic strategies, including vaccines.
• Subunit vaccine development is a key focus due to the lack of effective treatments.

Purpose of the Study:

• To review promising outer membrane protein (Omp) subunit vaccine candidates for Acinetobacter baumannii.
• To highlight the potential of Omps like OmpA, Omp34, Omp22, and BamA.
• To discuss challenges hindering the regulatory approval of A. baumannii vaccines.

Main Methods:

• Review of preclinical studies and reverse vaccinology approaches.
• Inclusion of nineteen subunit vaccine candidates with varying efficacy.
• Analysis of outer membrane proteins based on conservancy, antigenicity, and protective immunity.

Main Results:

• Nineteen subunit vaccine candidates were identified, showing preclinical survival rates from 14% to 100%.
• Outer membrane proteins OmpA, Omp34, Omp22, and BamA demonstrate significant potential as vaccine targets.
• Despite promising candidates, no licensed A. baumannii vaccine is currently available.

Conclusions:

• Outer membrane proteins are strong candidates for Acinetobacter baumannii vaccines.
• Challenges such as study inconsistencies, antigen variability, and insolubility must be addressed.
• Further research, standardization, and innovative technologies like nucleic acid vaccines are needed for regulatory approval.